ZEAL stock: buy or sell?
July 15th, 2019
Zealand Pharma A\u002FS, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark.
Should I buy ZEAL stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Zealand Pharma A/S stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Zealand Pharma A/S stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we found 1 rating published for ZEAL stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-7||Needham & Company LLC||n/a||Buy|
ZEAL stock analysis
Shares of Zealand Pharma A/S ended today at $21.96 and decreased a lame -1.08%.
Zealand Pharma A/S shares decreased -1.08% to $21.96 today. Since SMA100d and SMA200d crossed up on April, ZEAL price climbed $3.66 per share (20.00%). On July/2, ZEAL hit new all time highs, pushing higher previous ATH of $22.22 recorded on May. New ATHs are usual entry points for many trading setups as there aren't higher resistences. Since price and SMA200d lines crossed up on February, ZEAL climbed $7.66 (53.57%).
Zealand Pharma A/S shares depreciated -1.08% this week, ending at $21.96.
Zealand Pharma A/S stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, ZEAL might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last price record Zealand Pharma A/S marked early July. Since SMA20d and SMA40w crossed up early April, ZEAL price climbed $2.79 per share (14.55%). Since price and SMA40w lines crossed up late January, ZEAL climbed $7.92 (56.41%).
ZEAL stock price history
ZEAL IPO was on August 9th, 2017 at $18.12 per share1. Since then, ZEAL stock surged a 21.20%, with an average of 21.20% per year. If you had invested right after ZEAL's IPO a $1,000 in ZEAL stock in 2017, it would worth $212.00 today.
1: Adjusted price after possible price splits or reverse-splits.
ZEAL stock historical price chart
ZEAL stock reached all-time highs on July/2 with a price of $23.04.
ZEAL stock price target is $29.00How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we only found 1 price target for Zealand Pharma A/S stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-7||Needham & Company LLC||Reiterates||n/a||$29.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Zealand Pharma A/S didn't meet the estimates of the experts and posted a rough EPS of $-0.61 per share when experts were expecting $-0.69.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a spooky drop down of -72.14% to $37.98 million USD. Nevertheless, its earnings margin (compared to sales) climbed to 1,530.62%, that is $581.28 million.
|2013||$6.57 M||-||$-183.68 M-2795.7%||-|
|2014||$154 M||2,240.53%||$-64.99 M-42.3%||-64.62%|
|2015||$188 M||22.05%||$-113.96 M-60.7%||75.35%|
|2016||$235 M||25.10%||$-153.91 M-65.6%||35.06%|
|2017||$136 M||-41.94%||$-275.26 M-201.9%||78.84%|
|2018||$38 M||-72.14%||$581 M1530.6%||-311.18%|
Quarterly financial resultsZealand Pharma A/S posted $13.12 million in revenues for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter income marked $-122.97 M with a profit margin of -937.37%. Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Zealand Pharma A/S sales marked a super good gain and skyrocketed a 24.67%.
|2017-Q1||$78 M||-||$-26 M-33.9%||-|
|2017-Q2||$11 M||-86.09%||$-94 M-867.4%||255.79%|
|2017-Q3||$6 M||-41.44%||$-7 M-105.5%||-92.88%|
|2017-Q4||$11 M||66.39%||$-111 M-1051.6%||1,559.25%|
|2018-Q1||$11 M||2.91%||$-91 M-844.1%||-17.40%|
|2018-Q2||$15 M||39.77%||$-127 M-840.1%||39.12%|
|2018-Q4||$13 M||-13.33%||$-123 M-937.4%||-3.29%|
Zealand Pharma A/S ownershipWhen you are planning to invest in shares of a company, it's always worth to review its ownership structure.
Zealand Pharma A/S shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.
In case of Zealand Pharma A/S stock, 9.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ZEAL stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$675.3 M|
|Total shares||30.8 M|
|Float shares||27.3 M|
|- Institutional holdings (%)||9.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Monday, July 15th, 2019|
|Day range||$21.96 - $22.19|
|Average true range||$0.47|
|50d mov avg||$21.02|
|100d mov avg||$18.79|
|200d mov avg||$16.41|
Zealand Pharma A/S performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Zealand Pharma A/S against in the following table: